Popular Articles

Boston Scientific's Urology/Gynecology Products Featured In Studies At International Urogynecological Association Annual Meeting
Boston Scientific Corporation (NYSE: BSX) announced that results from nine studies involving the Company"s Urology/Gynecology products will be presented at the 34th Annual Meeting of the International Urogynecological Association (IUGA). Presentations will feature Boston Scientific"s pelvic floor reconstruction systems and mid-urethral sling systems used to treat pelvic floor prolapse and stress urinary incontinence (SUI). The Company will also sponsor a symposium highlighting long-term registry data comparing the benefits of experienced-based versus evidence-based outcomes for patients treated with mid-urethral slings. The IUGA Congress will be held June 16-20 at the Villa Erba Conference Center in Como, Italy.
generic viagra online
US Oncology Research Network Participates In Phase III Follow-up Study To BiPar's Investigational Cancer Drug BSI-201
US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences" Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.
News of the day
Getting Obese Mice Moving And Curing Their Diabetes
Mice lacking the fat hormone leptin or the ability to respond to it become morbidly obese and severely diabetic - not to mention downright sluggish. Now, a new study in the June Cell Metabolism shows that blood sugar control in those animals can be completely restored by returning leptin sensitivity to a single class of neurons in the brain, which account for only a small fraction of those that normally carry the hormone receptors.
Mental Health

Human Term Placenta A New Abundant Of Hematopoietic Cells

Investigators at Children"s Hospital Oakland Research Institute, Oakland, California found a way to obtain large numbers of hematopoietic stem cell from human term placenta. The results, which appear in the July 2009 issue of Experimental Biology and Medicine, describe detailed report on quantification, characterization, engraftment capacity, and most importantly, practical way to obtain hematopoietic stem cells from placenta in numbers that are several-fold higher than could be obtained from cord blood. The research team, Dr. Vladimir Serikov, MD, PhD, D.Sci, Assistant Staff Scientist, Catherin Hounshell, a research associate, Sandra Larkin, a research associate, Mr. William Green, student, Dr. Hurokazy Ikeda, MD, Visiting Scientist, Dr. Mark Walters, Medical Director of Children"s Hospital Oakland Hematology and Oncology Programs, and Dr. Frans Kuypers, Senior Scientist, performed studies in human term placentas, human cord blood, and immunodeficient mice. Dr. Serikov said, that the fact the human term placenta is a hematopoietic organ was reported by our team for the first time more then a year ago, and this year this finding was confirmed by UCSF scientists headed by Dr. S. Fisher. In this report, said Dr. Serikov, we demonstrate for the first time that human placentas could provide abundant amounts of CD34+ CD133+ colony-forming cells, as well as other primitive hematopoietic progenitors, suitable for transplantation in humans. The total amount of live hematopoitic stem cells, or colony-forming units in culture that could be obtained from placentas was an order of magnitude larger than the number of hematopoietic stem cells obtained from cord blood from the same . Hematopoietic stem cells which maintain their differentiation capacity, as well as stromal stem cells that support long-term culture of hematopoietic cells, can be harvested from perfusate of placenta following CXCR4 receptor blockade, said Dr. F. Kuypers. Importantly, live HPCs can similarly be obtained from whole cryopreserved placentas. Cells derived from placental tissue differentiated into all blood lineages in vitro. Animal experiments further demonstrated successful engraftment of placenta-derived HSC, which reconstituted hematopoiesis in immunodeficient mice. In summary, said Dr. F. Kuypers, our results indicate for the first time that human term placenta is a high capacity of live and functional hematopoietic stem cells. By using placental circulation and stem cell receptor blockade an abundant amounts of hematopoietic stem cell could be easily obtained in sterile conditions by non-destructive methods. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "the outstanding importance of these results for practical hematology is determined by the fact that total number of stem cells that can be harvested from cord blood limits the efficacy of this stem cell for transplants only to small children. These novel findings demonstrate that placenta may provide a of autologous stem cells sufficient for reconstitution of hematopoiesis in adult patients. Use of methods to obtain hematopoietic cells from placenta, developed by Dr. Serikov and Dr. Kuypers as augumentation of cord blood-based therapy or replacement of bone marrow for transplantation will dramatically change whole field of transplantology." Dr. Frans Kuypers Society for Experimental Biology and Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):